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Nano hemostat solution: immediate hemostasis at the nanoscale 3 Rutledge G. Ellis-Behnke, PhD, a,b,c, 4 Yu-Xiang 26 27 Through the ages doctors have found ways to achieve 28 hemostasis, beginning with the simple act of applying 29 pressure, then cauterization, ligation, and clinically induced 30 vasoconstriction [1 -10], but nanotechnology brings new 31 possibilities for changes in medical technology. Here we 32 present a novel method to stop bleeding using materials that 33 self-assemble at the nanoscale when applied to a wound. This 34 method results in the formation of a nanofiber barrier that 35 stops bleeding in any wet ionic environment in the body; 36 furthermore, the material is broken down into natural l-amino 37 acids that can be used by the surrounding tissue for repair.
38 Currently there are three basic categories of hemostatic 39 agents or procedures: chemical, thermal, and mechanical 40 [1, 3, 6, 8, [10] [11] [12] [13] [14] [15] . Chemical agents are those that change 41 the clotting activity of the blood or act as vasoconstrictors, 42 such as thromboxane A2 [16] , which causes vessels to 43 contract thus reducing blood flow and promoting clotting 44 [7, 16, 17] . Thermal devices commonly involve cauterization 45 using electrodes, lasers [8, 14] , or heat. There are also agents 46 that react exothermically upon application that may 47 create an effect similar to a standard two probe cautery 48 device [1, 14] . Mechanical methods use pressure or ligature 49 to slow the blood flow [3] . A combination therapy might use 50 both chemical and mechanical means to produce a he-51 mostat that adsorbs fluid and swells [18] , producing 52 pressure to slow the blood flow and allow clotting, or it 53 may involve the introduction of fibrinogen, thrombin, and
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54 calcium to produce fibrin glue, which acts as an artificial 55 clot [1, 2, 5, 6, 8, 10, 14, 19] . 56
There are five major issues related to the limitations and 57 applicability of many of these hemostatic agents. First, some 58 of the materials are solid, such as powder formulations, and 59 are not able to flow into the area of injury to bring about their 60 hemostatic effects [1, 10, 14] ; second, some liquid agents, 61 such as cyanoacrylates, require a dry environment to be 62 effective [8] ; third, some materials can create an immune 63 response resulting in the death of adjacent cells, placing ad-64 ditional stress on the body that can prolong or prevent healing 65 [8,10,14,15,20]; fourth, some agents have a short shelf-life 66 and very specific handling requirements [6, 10, 14, 16, 17] ; and 67 finally, many currently used hemostats are difficult to use in 68 uncontrolled environments [1, 7, 8, 10, 14] . Moreover, if a 69 therapy uses swelling as part of its hemostatic action, then 70 extra care must be taken to ensure that the local blood supply 71 is not reduced or stopped, which could cause additional tissue 72 damage or even death. This is particularly crucial when using 73 expanding foams [19] . Many hemostatic agents must be 74 prepared just before use because of their short shelf-life. 75 Surgical instruments, such as cauterization devices, clamps 76 and clips, must be used by a skilled individual in a controlled 77 environment [2, 5, [8] [9] [10] 16, 20] . 78
Our discovery, observed during a neurosurgical proce-79 dure, introduces a new way to stop bleeding using a self-80 assembling peptide that establishes a nanofiber barrier and 81 incorporates it into the surrounding tissue to form an 82 extracellular matrix (ECM). Surmising that nanotechnology 83 might be useful in our central nervous system regeneration 84 studies, we injected the material into wound sites in the brain 85 of hamsters to determine whether it would facilitate neuronal 86 regeneration [21] . To our surprise, it also stopped bleeding. 87
We then wanted to know if the rapid hemostasis that we 88 had observed in our nerve regeneration experiments was 89 tissue specific or would also work in other tissues. The seven 90 experiments we designed and performed demonstrate that in 91 less than 15 seconds complete hemostasis can be achieved 92 after (1) a transection of a blood vessel leading to the superior 93 sagittal sinus in both hamsters and rats, (2) a spinal cord cut, 94 (3) a femoral artery cut, (4) a sagittal transection of the left 95 lateral liver lobe, (5) a transverse transection of the left lateral 96 liver lobe including a cut in a primary branch of the portal 97 vein, (6) a 4-mm liver punch biopsy, and (7) multiple 4-mm 98 skin punch biopsies on nude mice.
99

Materials and methods
100
Adult Syrian hamsters were anesthetized with an intra-101 peritoneal injection of sodium pentobarbital (50 mg/kg), and 102 adult rats were anesthetized with an intraperitoneal injection 103 of ketamine (50 mg/kg 
109
Cortical vessel cut experiment
110
The animals were fitted in a head holder. The left lateral 111 part of the cortex was exposed, and each animal received a 112 transection of a blood vessel leading to the superior sagittal 113 sinus ( Figure 1, A) . With the aid of a sterile glass micro-114 pipette, 20 lL of 1% NHS-1 solution Q3 (see below under 115 bPreparation of the self-assembling solutionsQ) was applied to 116 the site of injury or iced saline in the control cases. The 117 animals were allowed to survive for as long as 6 months.
118
Spinal cord injury experiment 119
Under an operating microscope, the second thoracic 120 spinal cord segment (T2) was identified before performing a Rats were placed on their backs, and the hind limb was 130 extended to expose the medial aspect of the thigh (Figure 1 , 131 B). The skin was removed, and the overlying muscles were 132 cut to expose the femoral artery and sciatic nerve. The 133 femoral artery was cut to produce a high-pressure bleeder 134 (Figure 2 , F). With a 27-gauge 3 needle, 200 lL of 1% NHS-135 1 solution was applied over the site of injury. In two cases 136 we applied the dry powder of Q4 NHS-1 to the injury site, 137 which also was effective. (Data are not shown and were not 138 included in the analysis.) Controls were treated with a 139 combination of saline and pressure with a gauge. All 140 animals were killed 4 hours after the experiment.
Liver wound experiments 142
Rats were anesthetized and placed on their back, and 143 the abdomen was opened exposing the liver (Figure 1 , C). 144 The left lobe of the liver was cut using a scalpel in the 145 rostral-to-caudal direction, separating the two halves of the 146 lobe ( Figure 3 , B) in the sagittal cut. With a 27-gauge 147 needle, 100 lL of 1% or 2% NHS-1, NHS-2, 5
or TM-3 148 solution was applied to the site of injury (Figure 3 , B). 149 Livers of the controls were treated with saline or 150 cauterized. Cauterization was performed using a thermal 151 cautery device and was applied to the entire surface of the 152 injury. In another group of 28 adult rats the same 153 procedure was followed for the liver, which was cut 154 transversely ( Figure 3, D) . With a 27-gauge needle, 400 lL 155 of 1%, 2%, 3%, or 4% NHS-1 or TM-3 solution was applied 156 to the Q7 site of injury (Figure 3 , H).
157 In another group of anesthetized adult rats the liver was 158 exposed, and a 4-mm punch biopsy done from the ventral 159 aspect through the liver to the dorsal surface of the left liver 160 lobe. The resulting core was removed from the liver, after 161 which one of three treatments was applied. For the treatment 162 group 200 lL of 3% NHS-1 solution was applied to the site 163 of injury, whereas in the controls either saline was applied or 164 cauterization of the exposed liver surface was carried out.
165 The superficial material was then wiped clear of the injury 166 site. The abdominal incision was closed, and the animals 167 were allowed to survive for as long as 8 weeks.
168
Skin punch experiment 169
In anesthetized adult nude mice using aseptic precautions, 170 a 4-mm punch was used to create three wounds on each side 171 of the back of the animal. On one side of the animal the 172 wounds created were treated with 1% NHS-1 Q7 solution, and 173 the wounds on the opposite side were left untreated to provide 174 a control. The punch biopsies were made through the full 175 thickness of the skin. If the wound did not bleed for 176 10 seconds the punch would be excluded from the data 177 analyzed. All procedures were videotaped, and the analysis 178 consisted of reviewing the tapes. The animals were allowed to 179 survive for as long as 2 months. If animals involved in any of 180 the above experiments appeared to experience any discomfort 181 they were euthanized. 
Q6
overlying skull has been removed in an adult rat, and one of the veins of the superior sagittal sinus is transected and treated with 1% self-assembling NHS-1. A, The brain and veins of the superior sagittal sinus (SSS) are exposed. B, Cutting of the vein (arrow). C, Bleeding of the ruptured vein (arrow). D, The same area 5 seconds after application of the self-assembling NHS-1 to the location of the cut (arrow) as seen under the clear NHS-1. E-H, Rat femoral artery hemostasis. Exposure of the neurovascular bundle in the thigh showing the sciatic nerve (*) in each panel. E, Femoral artery and vein exposed. F, Cutting of the artery (arrow). G, Bleeding, masking the artery completely and sciatic nerve partially. H, The same area 5 seconds after application of the self-assembling peptide to the cut (arrow). Note that there is complete hemostasis in the area formed by NHS-1 (covering the entire picture) as it self-assembles in the presence of blood and plasma, revealing the underlying structures. Complete hemostasis was achieved in 10.6 F 4.1 seconds, significantly different from 367.5 F 37.7 seconds in controls irrigated with saline ( P N .0001). Scale bars represent 1 mm.
In the brain and liver of anesthetized adult rats a 1% or 184 2% NHS-1 solution was injected immediately after making 185a cut, and the treatment site was sampled. Samples were 186fixed in a mixture of 2% Q9 paraformaldehyde and 2.5% 187glutaraldehyde in 0. 213 Laboratory, Cambridge, MA) were prepared using the same 214 method. The time of preparation did not affect the action of 215 the solution. We also tested some material that was prepared 219Results 220Hemostasis in a brain injury 221 We began our experiments in the brain, removing the 222overlying skull and performing a complete transection of a 223branch of the superior sagittal sinus in the brain of rats (n = 22415) and hamsters (n = 15) ( Figure 1, A) . The areas were 225treated with 20 lL of a 1% solution of RADA16-I (NHS-1) 226self-assembling solution or with iced saline. In the groups 227treated with NHS-1 hemostasis Q13
was achieved in less than 10 228seconds in both hamsters and rats (Figure 2 , A-D and 229Supplemental Q14
Video 1, bHemostasis in rat cortex with self-230assembling peptide treatmentQ). Control group hamsters 231(n = 5) and rats (n = 5) irrigated with saline bled for more 232than 3 minutes (Figure 4, A) . A truncated iced-saline control 233 and subsequent treatment with NHS-1 is shown in 234 Supplemental Q16 Video 2 (bSaline control and treatment with 235 self-assembling peptide in rat cortex.Q) StudentTs t-test for 236 two independent samples in both hamsters and rats showed 237 highly significant differences (P b .0001).
238
Hemostasis in a spinal cord injury 239
Because blood has been shown to be toxic in neural tissue 240 [24] we wanted to know if the spinal environment was 241 different from the brain. By quickly bringing bleeding under 242 control secondary damage caused by surgery can be reduced.
243 After laminectomy and removal of the dura, the spinal cord 244 was hemisected at T2, from the dorsal to ventral aspect, 245 and treated (n = 5) with 20 ll of Q17 1% NHS-1. Hemostasis 246 was achieved in just over 10 seconds. In the saline controls 247 (n = 5) bleeding continued for as long as 5 minutes.
248 Comparison of the treated group and the saline controls 249 shows a significant difference using the Tukey test with a 250 99% confidence interval. 
Q15
durations in cases treated with 1% NHS-1 self-assembling solution compared with those cautery-and saline-treated controls for brain, femoral artery, and liver cuts (A), liver punches (B), and skin punches (C). Each bar shows the mean time in seconds for NHS-1-treated cases (in red), saline controls (in blue), and cautery controls (in yellow). A, In the rat brain cut, durations were measured from the start of application of self-assembling NHS-1 to the completion of hemostasis after transection of the veins leading to the superior sagittal sinus in the brain of adult rats. Complete hemostasis was achieved in 8.4 F 2.1 seconds. In the saline controls bleeding continued until 227.0 F 36.6 seconds. In the hamster brain cut, complete hemostasis was achieved in 9.0 F 1.8 seconds. In the saline controls bleeding continued until 187.6 F 34.7 seconds. In the femoral artery cut, complete hemostasis was achieved in 10.5 F 4.1 seconds. In the saline controls bleeding continued until 367.5 F 37.7 seconds. In the liver sagittal cut, complete hemostasis was achieved in 8.6 F 1.7 seconds. In the cautery control (yellow), bleeding continued until 90.0 F 5.0 seconds, and the saline controls bled for 301.6 F 33.2 seconds. B, Liver 4-mm punch biopsy. A 4-mm core was removed from the left liver lobe, and the hole was treated with NHS-1, heat cautery, or saline. Treatment with 3% NHS-1 brought about complete hemostasis in 9.7 F 1.2 seconds. In the cautery controls (yellow) bleeding continued for 81.2 F 6.7 seconds, and the saline controls bled for 204.3 F 49.6 seconds. C, Skin 4-mm punch biopsy. A 4-mm punch biopsy was made on the backs of nude mice. The biopsy extended through the dermis, and the core was removed. Care was taken not to disrupt the underlying muscle. The three wounds on one side were treated with 1% NHS-1, and complete hemostasis was achieved in 6.4 The femoral artery of 14 adult rats was surgically exposed, 253transacted, and then treated Q17
with 200 lL of a 1% solution of 254NHS-1 or iced saline and packing (Figure 2, E-H) . In the 255treated rats (n = 10) about 10 seconds elapsed before 256hemostasis occurred (Figure 4, A) . The controls (n = 4) 257continued to bleed for more than 6 minutes. The difference in 258times to achieve complete hemostasis was highly significant 259(StudentTs t-test P b .0001).
260Hemostasis in highly vascularized liver wounds 261 Using a group of 76 rats, we performed three different 262liver cuts: (1) a sagittal (rostrocaudal) cut (Figure 3, A and  263B) to test NHS-1 in an irregular-shaped laceration wound, 264(2) a transverse (lateral-medial) cut involving the transection 265of a major branch of the hepatic portal vein to intensify 266bleeding (Figure 3 , E-J), and (3) 4-mm punches through the 267liver lobe to observe the material in uniform wounds.
268
In the first liver experiment we made a sagittal cut in the 269 left lobe (n = 8); upon treatment with 100 lL of 1% NHS-1 270 solution bleeding ceased in less than 10 seconds (Figure 3 , 271 A-D and Supplemental Q18 Video 3, bSagittal cut of left liver 272 lobe using 1% self-assembling peptide Q19 treatmentQ). In one 273 set of controls (n = 3) bleeding stopped 90 seconds 274 (Figure 4, A) after cauterization of the wound; in the 275 saline-treated control animals (n = 3) bleeding continued 276 for more than 5 minutes. Comparison of the cauterized and 277 the saline-treated controls shows a significant difference 278 using the Tukey test with a 99% confidence interval.
279 In the second experiment we severed a major branch of the 280 portal vein while making a transverse cut in the left lobe to 281 test NHS-1 in a environment with a high flow rate. Four 282 concentrations of NHS-1 were tested (n = 12) along with 283 (n = 4) control animals. We applied Q19 400 lL of 4% 284 concentration NHS-1, and bleeding stopped in 11 seconds 285 (Figure 3 , E-J and Supplemental Q20 Video 4, bTransverse cut of 286 left liver lobe using 4% self-assembling peptide treatmentQ). This series of TEM images shows the interactions of NHS-1 with liver, cortex, and red blood cells. A, The left lateral lobe was treated with NHS-1, and the tissue was taken shortly after treatment. Note the hepatocyte and its nucleus (HN). There is a red blood cell (RBC) between the assembled NHS-1 (N-1) fields. Scale bar represents 2 Am. B, A closer look at the interface of the RBC and the material. Scale bar represents 50 nm. C, In the liver the RBC do not appear to mix with the NHS-1. Scale bar represents 1 Am. D, Application of 1% NHS-1 solution to a cut in the cortex. Note the close interface with the axons (Ax). Scale bar represents 0.2 Am. E, In another part of the brain the interface between the RBC and the NHS-1 appears to be similar to that in the liver. Scale bar represents 0.1 Am.
successfully with 400 lL of both 3% 288and 2% NHS-1 solution; bleeding ceased in 10 and 28910.3 seconds, respectively (Figure 4, D) . When 400 lL of 2901% NHS-1 was applied, Q21
bleeding continued for more than 29160 seconds (Figure 4, D) . The controls, however, bled for 292more than 6 minutes. The dose response shows that treatment 293results using 3% and 4% NHS-1 are nearly the same as with 294the 2% concentration. Furthermore, in the 2%, 3%, and 4% 295concentration treatment cases complete hemostasis was 296maintained after removing the excess assembled NHS-1 297material (Figure 3, I and J) . We found that the higher blood 298pressure/flow rate transverse liver cut required a concentra-299tion of 2% NHS-1 or higher to bring about complete 300hemostasis in less than 15 seconds. A significant difference 301was found between the Q21
NHS-1-treated and control groups 302using analysis of variance (ANOVA). When each treatment 303group was compared to the control group those differences 304were also significant; a Tukey test showed a 99% confidence 305interval. There was no significant difference when the 306various NHS-1 concentrations were compared, except for 307the 1% NHS-1 solution treatment group. 308 In the third experiment using adult rats (n = 45) we 309punched 4-mm holes through the left lateral lobe and then 310treated the area with 3% Q21
NHS-1, saline, or heat cautery to 311bring about hemostasis (Figure 4, B) . In the experimental 312group (n = 15) we applied a solution of 3% NHS-1 after 313injury and hemostasis was achieved in about 10 seconds, 314whereas the saline controls (n = 15) required 3.5 minutes to 315stop bleeding. In the heat cautery control group (n = 15) 316cessation of bleeding took more than 60 seconds, inclusive of 317applying heat to cauterize the inside surface of the punch. We 318allowed the NHS-1-treated animals to survive for as long as 6 319months with no detrimental effect on the tissues. Using 320ANOVA there was a significant difference between the 3% 321NHS-1 treatment and the controls (P b .0001). In addition, 322the Tukey test showed that each group was significantly 323different from the other with a 99% confidence interval.
324Hemostasis in skin punch biopsies 325 Six 4-mm punch biopsies were made on the backs of each 326of 23 anesthetized adult nude mice for a total of 138 punches. 327Three punches were treated with 1% NHS-1 solution and the 328other three were left untreated, except for dabbing with cotton 329every 15 seconds until bleeding stopped. Punched wounds 330that bled for less than 10 seconds were excluded from the 331experiment. We applied a solution of 1% Q21
NHS-1 10 seconds 332after injury (n = 23), and hemostasis took less than 33310 seconds; the controls (n = 23) continued to bleed for 334more than 60 seconds (Figure 4, C) . The bleeding times were 335averaged for each side of the animal, and the StudentTs t-test 336for paired samples showed a significant difference between 337the treatment and control side of the animal (P b .0001).
338Comparison of three different materials 339 To learn more about the hemostatic properties and 340mechanism of action of NHS-1 (RADA-16), we repeated 341 both the sagittal and transverse liver experiments, comparing 342 them with two additional materials that are known to self-343 assemble and spontaneously form nanofibers: (1) RADA-12 344 (NHS-2), a sequence variation of NHS-1, and (2) EAK-16 345 (TM-3), a different sequence in the same family of self-346 assembling peptides used to determine if the materialTs 347 length and stiffness altered its hemostatic effectiveness in 348 bleeding models [25] [26] [27] [28] [29] [30] [31] .
349 Making a sagittal liver cut in adult rats (n = 9) we 350 applied 100 lL of 2% NHS-2 solution to the wound, and 351 bleeding stopped in less than 10 seconds. In the cautery 352 controls (n = 3) bleeding continued for more than 353 90 seconds (P b .0001). Upon repetition of the experiment 354 in adult rats (n = 8) using 100 lL of 2% TM-3, Q21 the material 355 assembled but did not achieve hemostasis; the animals 356 continued to bleed until the experiment was terminated after 357 more than 3 minutes.
358 The increased blood flow from the portal vein after 359 making a transverse liver cut allowed us to perform another 360 dose response experiment in which we compared various 361 concentrations of NHS-1 (1% to 4%) and TM-3 (1% to 3%) 362 with controls (Figure 4, D) . All Q21 concentrations of NHS-1 363 were effective; however, the higher blood pressure and flow 364 rate after the transverse liver cut required a concentration of 365 2% or higher of NHS-1 to stop bleeding in less than 366 15 seconds. 367 TM-3 is a stiffer gel; 1% TM-3 is similar in stiffness to 368 3% NHS-1. We tried three different concentration levels 369 (1%, 2%, and 3%) and found that TM-3 was Q21 not effective at 370 any concentration; the assembled material fractured and the 371 TM-3-treated animals continued to bleed regardless of the 372 concentration used. There was actually no significant 373 difference between TM-3 and the controls (Figure 4, D) in 374 achieving hemostasis.
375
Interface of NHS-1 and tissues 376 Still looking for mechanism clues as well as further 377 understanding of the relationship of the NHS-1 blood/tissue 378 interface in both the brain and liver, we also examined the 379 treated tissues using transmission electron microscopy 380 (TEM), interested in learning how the red blood cells (RBCs), 381 platelets, tissue, and the ECM interact with the material.
382 We applied 1% NHS-1 to a liver wound and immediately 383 harvested the tissue. In the electron micrograph the hepato-384 cyte and RBC looks to be intact with the assembled NHS-1 at 385 the interface ( Figure 5, A) . When applied shortly after injury, 386 the material appeared to stop the movement of blood from the 387 vessels without detrimental effects to the liverTs RBCs; there 388 was also no evidence of lysing ( Figure 5, B) . Furthermore, 389 there was no evidence of platelet aggregation [32] at the 390 blood/NHS-1 interface (Figure 5 , C) when samples were 391 taken at various time points after treatment.
392 In the brain we found a very tight interaction between 393 NHS-1 and the neural tissue ( Figure 5, D) . We observed no 394 RBCs and no evidence of platelet aggregation in the 395 assembled NHS-1. The RBCs that were present appeared
396intact at the edges of the assembled NHS-1 with no evidence 397of lysing ( Figure 5, E) . Furthermore, no evidence of thrombi 398was observed in the brain, lung, or liver of the animals 399treated with NHS-1 and NHS-2.
400Discussion 401
Our study demonstrates that hemostasis can be achieved in 402 less than 15 seconds in multiple tissues as well as a variety of 403 different wounds. This is the first time that nanotechnology 404 has been used to stop bleeding in a surgical setting for animal 405 models and seems to demonstrate a new class of hemostatic 406 agent that does not rely on heat, pressure, platelet activation, 407 adhesion, or desiccation to stop bleeding. NHS-1 and NHS-2 408 are synthetic, biodegradable [10,19] and do not contain any 409 blood products, collagens, or biological contaminants that 410 may be present in human-or animal-derived hemostatic 411 agents such as fibrin glue [1, 8, 10, 14, 20] . They can be applied 412 directly onto, or into, a wound without the concern that the 413 material may expand, thus reducing the risk of secondary 414 tissue damage as well as the problems caused by constricted 415 blood flow. In our previous brain studies [21] we looked for 416 evidence of the production of prion-like substances or fibril 417 tangles in animals that had the material implanted in their 418 brain for as long as 6 months but found none. Furthermore, 419 the breakdown products of NHS-1 are amino acids, which 420 can be used by the body as tissue building blocks for the 421 repair of the injury [21] . Independent third-party testing of the 422 material found no pyrogenicity, which has been found with 423 some other hemostatic agents, and no systemic coagulation or 424 other safety issues in animals [33] .
425
The exact mechanism for the hemostasis reported here 426 is not fully understood, but we have uncovered several 427 clues. First, we know that the hemostasis is not explainable 428 by clotting. Blood clots are produced after injury, but do 429 not begin to form until 1 to 2 minutes have elapsed, de-430 pending upon the status and coagulation history of the 431 patient [6, 12, 34] . 432
Second, the electron micrographs show no evidence of 433 platelet aggregation at the interface of the material and wound 434 site. That arginine inhibits platelet aggregation suggests that 435 the arginine in NHS-1 plays a role in this effect [4,35 -37] ; 436 this seems to be consistent with our data. The NHS-1 and 437 NHS-2 solutions appear to self-assemble into a barrier, 438 stemming the flow of blood and facilitating the movement of 439 adjacent cells to repair the injured site [21] . 440
Third, in our experiments the NHS-1 and NHS-2 solutions 441 easily filled in and conformed to the irregular shapes of the 442 wounds before assembling, as shown in the electron micro-443 graphs. We believe this tight contact is crucial to the 444 hemostatic action because of the size of the self-assembling 445 peptide units. The micrographs also showed that the material 446 does not cause the RBCs to lyse, apparently protecting them 447 from normal degradation when exposed to the air. 448
Fourth, we do not believe that the hemostasis can be 449 explained by gelation kinetics. One would think that a stiffer 450 gel would be more effective for higher pressure bleeders; 451 however, we found the opposite to be true. TM-3, which is 452 from the same family of peptides as NHS-1 and NHS-2, and 453 is the stiffest of the three self-assembling peptides tested, did 454 not arrest bleeding; it fractured at the tissue interface and 455 within the resultant gel. We surmise that TM-3 may have 456 fractured because of (1) the pulsations of the liver and (2) 457 the inability of the material to flex with the tissue as blood 458 pumped through the organ. This is similar to the fracturing 459 of an artery when grown in a laminar flow environment and 460 then transplanted to a pulsed environment. The cells line up 461 along the direction of flow, unlike the natural helical coil 462 [38 -41] seen in a pulsed environment, which allows for 463 expansion and contraction, without splitting, as blood 464 moves though the artery. Conversely, NHS-1 and NHS-2 465 were able to flex with the tissue.
466 Finally, NHS-2, the most pliable of the Q22 three materials, 467 seemed to perform identically to NHS-1, probably as a 468 result of their similar structure and modulus.
469 With this discovery the ability to speedily achieve 470 hemostasis will reduce radically the quantity of blood needed 471 during surgery of the future. As much as 50% Q23 of surgical time 472 can be spent packing wounds to reduce or control bleeding.
473 The NHS solutions may represent a step change in 474 technology and could revolutionize bleeding control during 475 surgery and trauma; however, they still require clinical testing 476 before they can be used in humans.
477
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